Investigational and experimental GnRH analogs and associated neurotransmitters

References

• Newton CL, Anderson RC, Millar RP. Therapeutic neuroendocrine agonist and antagonist analogs of hypothalamic neuropeptides as modulators of the hypothalamic-pituitary-gonadal axis. Endocr Dev. 2016;30:106–129.
   PubMedGoogle Scholar
• Millar RP. GnRHs and GnRH receptors. Anim Reprod Sci. 2005;88:5–28.
   PubMed Web of Science ®Google Scholar
• Burstein HJ, Lacchetti C, Anderson H, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American society of clinical oncology clinical practice guideline update on ovarian suppression. J Clin Oncol. 2016;34:1689–1701.
   PubMed Web of Science ®Google Scholar
• McArdle GA,, Roberson MS. Gonadotropes and Gonadotropin-releasing hormone signaling. In: Knobil and Neill’s physiology or reproduction. 4th ed. Philadelphia. New York:Elsevier Inc; 2015. p. 335–397.
   Google Scholar
• Naor Z. Signaling by G-protein-coupled receptor (GPCR): studies on the GnRH receptor. Front Neuroendocrinol. 2009;30:10–29.
   PubMed Web of Science ®Google Scholar
• Millar RP, Lu ZL, Pawson AJ, et al. Gonadotropin-releasing hormone receptors. Endocr Rev. 2004;25:235–275.
   PubMed Web of Science ®Google Scholar
• Millar RP, Newton CL. Current and future applications of GnRH, kisspeptin and neurokinin B analogues. Nat Rev Endocrinol. 2013;9:451–466.
   PubMed Web of Science ®Google Scholar
• Karten MJ, Rivier JE. Gonadotropin-releasing hormone analog design. Structure-function studies toward the development of agonists and antagonists: rationale and perspective. Endocr Rev. 1986;7:44–66.
   PubMed Web of Science ®Google Scholar
• Sciarra A, Fasulo A, Ciardi A, et al. A meta-analysis and systematic review of randomized controlled trials with degarelix versus gonadotropin-releasing hormone agonists for advanced prostate cancer. Medicine (Baltimore). 2016;95:e3845.
   PubMed Web of Science ®Google Scholar
• Ratcliffe KE, Fraser HM, Sellar R, et al. Bifunctional gonadotropin-releasing hormone antagonist- progesterone analogs with increased efficacy and duration of action. Endocrinology. 2006;147:571–579.
   PubMed Web of Science ®Google Scholar
• Conn PM, Ulloa-Aguirre A. Pharmacological chaperones for misfolded gonadotropin-releasing hormone receptors. Adv Pharmacol. 2011;62:109–141.
   PubMedGoogle Scholar
• Conn PM. Rescue of gonadotropin hormone receptor mutants. US. 7,695,917. 2010. 2010.
   Google Scholar
• Noorwez SM, Kuksa V, Imanishi Y, et al. Pharmacological chaperone-mediated in vivo folding and stabilization of the P23H-opsin mutant associated with autosomal dominant retinitis pigmentosa. J Biol Chem. 2003;278:14442–14450.
   PubMed Web of Science ®Google Scholar
• Noorwez SM, Ostrov DA, McDowell JH, et al. A high-throughput screening method for small-molecule pharmacologic chaperones of misfolded rhodopsin. Invest Ophthalmol Vis Sci. 2008;49:3224–3230.
   PubMed Web of Science ®Google Scholar
• Conn PM, Ulloa-Aguirre A. Trafficking of G-protein-coupled receptors to the plasma membrane: insights for pharmacoperone drugs. Trends Endocrinol Metab. 2010;21:190–197.
   PubMed Web of Science ®Google Scholar
• Lahlou N, Roger M, Chaussain JL, et al. Gonadotropin and alpha-subunit secretion during long term pituitary suppression by D-Trp6-luteinizing hormone-releasing hormone microcapsules as treatment of precocious puberty. J Clin Endocrinol Metab. 1987;65:946–953.
   PubMed Web of Science ®Google Scholar
• Gonen Y, Balakier H, Powell W, et al. Use of gonadotropin-releasing hormone agonist to trigger follicular maturation for in vitro fertilization. J Clin Endocrinol Metab. 1990;71:918–922.
   PubMed Web of Science ®Google Scholar
• Lambertini M, Pescio MC, Viglietti G, et al. Methods of controlled ovarian stimulation for embryo/oocyte cryopreservation in breast cancer patients. Expert Rev Quality of Life in Cancer Care. 2017;2:47–59.
   Google Scholar
• Youssef MA, Van der VF, Al-Inany HG, et al. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology. Cochrane Database Syst Rev. 2014;10:CD008046.
   PubMed Web of Science ®Google Scholar
• Millar RP, Pawson AJ, Morgan K, et al. Diversity of actions of GnRHa mediated by ligand- induced selective signaling. Front Neuroendocrinol. 2008;29:17–35.
   PubMed Web of Science ®Google Scholar
• Blumenfeld Z, Zur H, Dann EJ. Gonadotropin-releasing hormone agonist cotreatment during chemotherapy may increase pregnancy rate in survivors. Oncologist. 2015;20:1283–1289.
   PubMed Web of Science ®Google Scholar
• Lambertini M, Del Mastro L, Pescio MC, et al. Cancer and fertility preservation: international recommendations from an expert meeting. BMC Med. 2016;14:1.
   PubMed Web of Science ®Google Scholar
• Coates AS, Winer EP, Goldhirsch A, et al. Tailoring therapies–improving the management of early breast cancer: St Gallen international expert consensus on the primary therapy of early breast cancer 2015. Ann Oncol. 2015;26:1533–1546.
   PubMed Web of Science ®Google Scholar
• Blumenfeld Z, Evron A. Preserving fertility when choosing chemotherapy regimens - the role of gonadotropin-releasing hormone agonists. Expert Opin Pharmacother. 2015;16:1009–1020.
   PubMed Web of Science ®Google Scholar
• Blumenfeld Z, Katz G, Evron A. ‘An ounce of prevention is worth a pound of cure’: the case for and against GnRH-agonist for fertility preservation. Ann Oncol. 2014;25:1719–1728.
   PubMed Web of Science ®Google Scholar
• Del Mastro L, Lambertini M. Temporary ovarian suppression with gonadotropin-releasing hormone agonist during chemotherapy for fertility preservation: toward the end of the debate? Oncologist. 2015;20:1233–1235.
   PubMed Web of Science ®Google Scholar
• Lambertini M, Ceppi M, Poggio F, et al. Ovarian suppression using luteinizing hormone-releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: a meta-analysis of randomized studies. Ann Oncol. 2015;26:2408–2419.
   PubMed Web of Science ®Google Scholar
• Lambertini M, Boni L, Michelotti A, et al. GIM study group. Ovarian suppression with triptorelin during adjuvant breast cancer chemotherapy and long-term ovarian function, pregnancies, and disease-free survival: a randomized clinical trial. Jama. 2015;314:2632–2640.
   PubMed Web of Science ®Google Scholar
• Moore HC, Unger JM, Phillips KA, et al. POEMS/S0230 Investigators. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med. 2015;372:923–932.
   PubMed Web of Science ®Google Scholar
• Paluch-Shimon S, Pagani O, Partridge AH, et al. Second international consensus guidelines for breast cancer in young women (BCY2). Breast. 2016;26:87–99.
   PubMed Web of Science ®Google Scholar
• Lambertini M, Cinquini M, Moschetti I, et al. Temporary ovarian suppression during chemotherapy to preserve ovarian function and fertility in breast cancer patients: a GRADE approach for evidence evaluation and recommendations by the Italian association of medical oncology. Eur J Cancer. 2017;71:25–33.
   PubMed Web of Science ®Google Scholar
• Topaloglu AK, Tello JA, Kotan LD, et al. Inactivating KISS1 mutation and hypogonadotropic hypogonadism. N Engl J Med. 2012;366:629–635.
   PubMed Web of Science ®Google Scholar
• Seminara SB, Messager S, Chatzidaki EE, et al. The GPR54 gene as a regulator of puberty. N Engl J Med. 2003;349:1614–1627.
   PubMed Web of Science ®Google Scholar
• De Roux N, Genin E, Carel JC, et al. Hypogonadotropic hypogonadism due to loss of function of the KiSS1-derived peptide receptor GPR54. Proc Natl Acad Sci USA. 2003;100:10972–10976.
   PubMed Web of Science ®Google Scholar
• Roseweir AK, Kauffman AS, Smith JT, et al. Discovery of potent kisspeptin antagonists delineate physiological mechanisms of gonadotropin regulation. J Neurosci. 2009;29:3920–3929.
   PubMed Web of Science ®Google Scholar
• Topaloglu AK, Reimann F, Guclu M, et al. TAC3 and TACR3 mutations in familial hypogonadotropic hypogonadism reveal a key role for neurokinin B in the central control of reproduction. Nat Genet. 2009;41:354–358.
   PubMed Web of Science ®Google Scholar
• Young J, Bouligand J, Francou B, et al. TAC3 and TACR3 defects cause hypothalamic congenital hypogonadotropic hypogonadism in humans. J Clin Endocrinol Metab. 2010;95:2287–2295.
   PubMed Web of Science ®Google Scholar
• Young J, George JT, Tello JA, et al. Kisspeptin restores pulsatile LH secretion in patients with neurokinin B signaling deficiencies: physiological, pathophysiological and therapeutic implications. Neuroendocrinology. 2013;97:193–202.
   PubMed Web of Science ®Google Scholar
• Rance NE, Dacks PA, Mittelman-Smith MA, et al. Modulation of body temperature and LH secretion by hypothalamic KNDy (kisspeptin, neurokinin B and dynorphin) neurons: a novel hypothesis on the mechanism of hot flushes. Front Neuroendocrinol. 2013;34:211–227.
   PubMed Web of Science ®Google Scholar
• Prague JK, Roberts RE, Comninos AN, et al. Neurokinin 3 receptor antagonism as a novel treatment for menopausal hot flushes: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 2017. published online April 3. DOI:10.1016/S0140-6736(17)30823-1
   PubMed Web of Science ®Google Scholar
• Skorupskaite K, George JT, Veldhuis JD, et al. Neurokinin 3 receptor antagonism reveals roles for neurokinin B in the regulation of gonadotropin secretion and hot flashes in postmenopausal women. Neuroendocrinology. 2017 Apr 5. [Epub ahead of print]. DOI:10.1159/000473893
   PubMedGoogle Scholar
• Sassarini J, Anderson RA. New pathways in the treatment for menopausal hot flushes. Lancet. 2017 Apr 3. pii: S0140-6736(17)30886-3. [Epub ahead of print]. DOI:10.1016/S0140-6736(17)30886-3.
   PubMed Web of Science ®Google Scholar
• Comninos AN, Wall MB, Demetriou L, et al. Kisspeptin modulates sexual and emotional brain processing in humans. J Clin Invest. 2017;127:709–719.
   PubMed Web of Science ®Google Scholar